TY - JOUR
T1 - Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
AU - for the Dominantly Inherited Alzheimer Network
AU - Schultz, Stephanie A.
AU - Strain, Jeremy F.
AU - Adedokun, Adedamola
AU - Wang, Qing
AU - Preische, Oliver
AU - Kuhle, Jens
AU - Flores, Shaney
AU - Keefe, Sarah
AU - Dincer, Aylin
AU - Ances, Beau M.
AU - Berman, Sarah B.
AU - Brickman, Adam M.
AU - Cash, David M.
AU - Chhatwal, Jasmeer
AU - Cruchaga, Carlos
AU - Ewers, Michael
AU - Fox, Nick N.
AU - Ghetti, Bernardino
AU - Goate, Alison
AU - Graff-Radford, Neill R.
AU - Hassenstab, Jason J.
AU - Hornbeck, Russ
AU - Jack, Clifford
AU - Johnson, Keith
AU - Joseph-Mathurin, Nelly
AU - Karch, Celeste M.
AU - Koeppe, Robert A.
AU - Lee, Athene K.W.
AU - Levin, Johannes
AU - Masters, Colin
AU - McDade, Eric
AU - Perrin, Richard J.
AU - Rowe, Christopher C.
AU - Salloway, Stephen
AU - Saykin, Andrew J.
AU - Sperling, Reisa
AU - Su, Yi
AU - Villemagne, Victor L.
AU - Vöglein, Jonathan
AU - Weiner, Michael
AU - Xiong, Chengjie
AU - Fagan, Anne M.
AU - Morris, John C.
AU - Bateman, Randall J.
AU - Benzinger, Tammie L.S.
AU - Jucker, Mathias
AU - Gordon, Brian A.
N1 - Publisher Copyright:
© 2020
PY - 2020/8
Y1 - 2020/8
N2 - Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of neuronal damage in neurodegenerative diseases. However, there have been limited investigations relating NfL to the concurrent measures of white matter (WM) decline that it should reflect. White matter damage is a common feature of Alzheimer's disease. We hypothesized that serum levels of NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a subset (N = 41) of MC with longitudinal NfL and MRI data. In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and negatively with fractional anisotropy. Greater change in NfL levels in MC was associated with larger changes in fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of reduced WM integrity. There were no relationships with NfL in NC. Our results demonstrate that blood-based NfL levels reflect WM integrity and supports the view that blood levels of NfL are predictive of WM damage in the brain. This is a critical result in improving the interpretability of NfL as a marker of brain integrity, and for validating this emerging biomarker for future use in clinical and research settings across multiple neurodegenerative diseases.
AB - Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of neuronal damage in neurodegenerative diseases. However, there have been limited investigations relating NfL to the concurrent measures of white matter (WM) decline that it should reflect. White matter damage is a common feature of Alzheimer's disease. We hypothesized that serum levels of NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a subset (N = 41) of MC with longitudinal NfL and MRI data. In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and negatively with fractional anisotropy. Greater change in NfL levels in MC was associated with larger changes in fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of reduced WM integrity. There were no relationships with NfL in NC. Our results demonstrate that blood-based NfL levels reflect WM integrity and supports the view that blood levels of NfL are predictive of WM damage in the brain. This is a critical result in improving the interpretability of NfL as a marker of brain integrity, and for validating this emerging biomarker for future use in clinical and research settings across multiple neurodegenerative diseases.
KW - Alzheimer's disease
KW - Blood-based biomarkers
KW - Neurodegeneration
KW - Neurofilament
KW - Neuroimaging
KW - White matter
UR - http://www.scopus.com/inward/record.url?scp=85086156081&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2020.104960
DO - 10.1016/j.nbd.2020.104960
M3 - Article
C2 - 32522711
AN - SCOPUS:85086156081
SN - 0969-9961
VL - 142
JO - Neurobiology of Disease
JF - Neurobiology of Disease
M1 - 104960
ER -